The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown - 07/12/23

Abstract |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.
El texto completo de este artículo está disponible en PDF.Key words : Asthma, COVID-19, type 2 inflammation, ACE2 receptor, biologic, allergen immunotherapy, antiviral mechanisms, exacerbations, vaccine, immunophenotyping assessment of COVID-19
Abbreviations used : ACE2, AIT, ICS, ILC2, pDC, SARS-CoV-2, TLR, TMPRSS2
Esquema
Vol 152 - N° 6
P. 1376-1381 - décembre 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.